Results
Bio‑Rad Cuts 2026 Outlook, Shares Drop 9.5%
Bio‑Rad shares fell 9.5% to $253.48 after cutting its 2026 revenue outlook to –3% to +0.5% from prior 0.5%‑1.5% growth range.
First‑quarter net loss of $527.1 million versus $64 million profit a year
